ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypert
May 17, 2021ReCor Medical, Inc., a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO ("TRIO") study. -
TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History
July 10, 2018Translational Research In Oncology (TRIO) today announced a collaboration with Novartis on its upcoming phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The tr
Pharma Sources Insight January 2025
